DHHS supporting new Ebola treatment
The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) is providing support and expertise to Ridgeback Biotherapeutics to manufacture an investigational treatment for Ebola virus disease. The therapeutic, mAb114, is a single monoclonal antibody that binds to a virus protein, reducing its ability to infect human cells. The product received FDA Breakthrough Therapy Designation, which helps facilitate development, and is currently being offered to Ebola patients in the Democratic Republic of the Congo as part of a clinical trial co-sponsored by the U.S. National Institute of Allergy and Infectious Diseases and the Congo National Biomedical Research Institute and being coordinated by the World Health Organization. Read the HHS news release.